Hindustan Bio Sciences Limited (BSE: 532041)
Health Care · Biotechnology · IN
Rs6.71
-3.17% today · -18.2% 1Y
Hindustan Bio Sciences Limited (BSE: 532041) operates in the Biotechnology industry within the Health Care sector. The company is valued at $718.89K.
Over the last twelve months the share price has lost 18.2%, trading between 5.00 and 9.92.
Tweenvest scores Hindustan Bio Sciences Limited across four factors: quality 49/100, value 56/100, growth 0/100. Its strongest factor is value.
532041 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $718.89K
- Revenue (TTM)
- $42.53K
- P/E
- —
- EPS
- -0.23
- Dividend yield
- —
- Beta (5Y)
- -0.66
- 52-week high
- Rs9.92
- 52-week low
- Rs5.00
- Avg volume (3M)
- —
- Shares outstanding
- 10.25M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.41 | -0.04% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.54 | +1.91% |
Figures last refreshed Aug 18, 2026.